Adding a fourth certified facility within its global network increases operational capacity to better serve international medical markets NASDAQ | TSX: ACB Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "cont ...

Core Points - Aurora Cannabis Inc. has filed and mailed the management information circular for the upcoming annual general and special meeting of shareholders [1] - The meeting is scheduled to be held virtually on August 8, 2025, at 1:00 p.m. Eastern time [2] - Shareholders are encouraged to vote their shares by the deadline of August 6, 2025, at 1:00 p.m. Eastern time [3] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [4] - The company offers a diverse portfolio of adult-use and medical cannabis brands, including Drift, San Rafael '71, MedReleaf, and others [4] - Aurora holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [4] Shareholder Engagement - Shareholders can access the management information circular on the company's website and are encouraged to watch a message from the CEO and CFO reflecting on fiscal 2025 [2] - The company emphasizes the importance of shareholder participation and provides contact information for assistance with voting [3]

Core Insights - Aurora Cannabis Inc. has launched two new proprietary cultivars in Poland, marking the highest potency medical cannabis products available in the country [1][2] - The new products, Farm Gas and Sourdough, are designed to meet the demand for high-quality, high-potency medical cannabis among prescribers and patients [2][3] - Aurora emphasizes its leadership in the international medical cannabis market, leveraging its scientific expertise and understanding of regulatory landscapes [3] Product Details - Farm Gas has a THC content of 27% and less than 1% CBD, with a unique aroma profile featuring notes of kerosene, diesel, and a sweet fruit sherbet finish [7] - Sourdough boasts a THC content of 29% and less than 1% CBD, characterized by sour, cake, and gasoline notes in its aroma profile [7] - Both cultivars are hang-dried and hand-finished, showcasing the company's commitment to quality [2] Company Overview - Aurora Cannabis Inc. operates in the medical and consumer cannabis markets across Canada, Europe, Australia, and New Zealand [4] - The company is known for its diverse brand portfolio, including both medical and adult-use cannabis brands [4] - Aurora holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants in North America [4]

Market Performance - Aurora Cannabis shares experienced a decline [1] - The company anticipates "temporary declines" in its international markets, including the U S [1]

Group 1: Earnings Performance - Aurora Cannabis Inc. reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share, representing a -36.36% earnings surprise [1] - The company posted revenues of $63.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.65%, compared to year-ago revenues of $49.98 million [2] - Over the last four quarters, Aurora Cannabis has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Aurora Cannabis shares have increased by approximately 38.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.7% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $0.17 on revenues of $69.13 million, and $0.44 on revenues of $268.33 million for the current fiscal year [7] Group 3: Industry Context - The Medical - Products industry, to which Aurora Cannabis belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aurora Cannabis's stock performance [5] - The Zacks Rank for Aurora Cannabis is currently 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

Exhibit 99.1 Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter NASDAQ | TSX: ACB EDMONTON, AB, June 18, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025. "We are pleased to report an exceptional year to our shareholders, highlighted by record annual global m ...

Industry Overview - Marijuana stocks have significant potential for high returns, although the market has faced challenges since the initial surge in 2018 [1] - Despite market fluctuations, companies are adapting to demand, with profits and revenues on the rise [1][3] - Current political concerns, particularly regarding Donald Trump's administration, have not significantly impacted the cannabis market [2] Company Highlights - **Aurora Cannabis Inc.**: Engages in the production and sale of cannabis products, recently completed a multimillion-dollar investment in a manufacturing facility, which has doubled yield and potency to a record 33.7% [4][5][6] - **Cronos Group Inc.**: Involved in the cultivation and distribution of cannabis products internationally, with an upcoming virtual Annual Meeting of Shareholders scheduled for April 28, 2025 [8][10] - **SNDL Inc.**: Operates in multiple segments including cannabis retail and reported Q1 2025 financial earnings with net revenue of $204.9 million, reflecting a growth rate of +3.6% [12][13] Financial Performance - Aurora Cannabis reported a significant increase in yield and potency, indicating strong operational performance [6] - SNDL Inc. achieved a gross profit of $56.6 million in Q1 2025, marking a growth of +12.4% and a gross margin of 27.6%, setting a new record for the company [13]

Industry Overview - The cannabis industry is experiencing consistent declines in stock prices despite long-term growth potential [1][2] - Investor confidence is low due to political uncertainty, particularly with Donald Trump's administration [2][3] Company Highlights - **Tilray Brands, Inc.**: Engages in the research, cultivation, processing, and distribution of medical cannabis products across multiple regions including Canada, the U.S., and Europe [4] - Recently ranked 4th in the Brewers Association 2024 annual report for top craft brewing companies in the U.S., up from 5th place, indicating growth in the craft brewing sector [6] - **Cronos Group Inc.**: Operates in the cultivation, production, distribution, and marketing of cannabis products internationally [7] - Anna Shlimak has been appointed as Chief Financial Officer, marking a significant leadership change within the company [9][10] - **Aurora Cannabis Inc.**: Involved in the production, distribution, and sale of cannabis products globally [10][12] - Recently launched the first inhalable resin cartridges for patients in the UK, Canada, and Australia, addressing a need for convenient consumption options [13]

Core Insights - Aurora Cannabis Inc. has been recognized in the Globe & Mail's 2025 Report on Business as an honouree in the Women Lead Here list, highlighting its commitment to gender diversity at the executive level [1][3] - The company boasts that 43% of its executive leadership team consists of women, emphasizing their role in driving change within the medical cannabis industry [2][3] - Aurora established the Women Empowerment Network (WEN) in 2022 to support the advancement of women within the organization, offering learning and community engagement opportunities [2] Company Overview - Aurora Cannabis Inc. is a leading global medical cannabis company based in Edmonton, Alberta, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [4] - The company's product portfolio includes various adult-use brands such as Drift, San Rafael '71, and medical cannabis brands like MedReleaf and CanniMed, among others [4] - Aurora is also a major player in the agricultural sector with a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants [4] Market Presence - Aurora's common shares are traded on NASDAQ and TSX under the symbol "ACB," indicating its established presence in the financial markets [5]

Core Insights - Aurora Cannabis Inc. is participating as a leader in the inaugural Global Cannabis Regulatory Summit (GCRS) in Washington, D.C. on March 26-27, 2025, highlighting its role in advocating for policy reform in the cannabis industry [1][2] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of adult-use brands including Drift, San Rafael '71, Daily Special, Tasty's, Being, and Greybeard, as well as medical cannabis brands such as MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. [3] - Aurora also holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [3] Industry Engagement - The GCRS will facilitate discussions among regulators, members of Congress, international policy experts, and cannabis industry executives to shape the future of the global cannabis industry [2][3] - Aurora's participation in panel discussions aims to enhance understanding of the distinctions between medical and adult-use cannabis, informed by international political and regulatory consensus [3]